Reducing Pain During Dental Nerve Block Injections in Children (IANB)

June 19, 2026 updated by: Samah Fadhil Mohamed-Ali, Al-Mustansiriyah University

Effect of External Cooling and Vibration, Counterstimulation, and Needle Type on Pain, Physiological, and Behavioral Outcomes During Inferior Alveolar Nerve Block in Pediatric Patients

Title of Study: Effect of External Cooling and Vibration, Counterstimulation, and Needle Type on Pain, Physiological, and Behavioral Outcomes During Inferior Alveolar Nerve Block in Pediatric Patients

Why was this study done? The inferior alveolar nerve block (IANB) is a dental injection used to numb the lower jaw and teeth in children. Many children find this injection very painful and scary. Bad experiences can make them afraid of the dentist for years. This study was designed to test different ways to make the injection less painful and stressful for children.

What did the researchers want to find out?

They planned to compare three different methods to see which one works best to reduce pain, distress, and physical signs of fear (like a fast heartbeat) during the injection:

External cooling + vibration (using a special device that cools and vibrates on the skin near the injection site)

Counterstimulation (gentle tapping or pressing with a cotton roll near the injection site)

A thinner needle (30-gauge instead of the standard 27-gauge)

Standard method (27-gauge needle with no extra distraction) - this is the control group

Who took part? The study enrolled 166 healthy children between the ages of 5 and 9 years who needed a lower jaw dental injection at Al-Mustansiriyah University Dental College.

What happened during the study?

Children were randomly placed into one of the four groups. All children received the same numbing medicine (2% lidocaine with epinephrine). Dentists gave the injection at the same speed for everyone. Researchers planned to measure:

How much pain the child felt (using the Wong-Baker Faces scale, where children point to a face showing their pain level)

How much pain the child showed (using the FLACC scale, which looks at face, legs, activity, crying, and comfort)

Heart rate and oxygen level (using a finger clip device)

How well the child cooperated (using the Frankl Behavior Rating Scale)

What outcomes are being measured? The primary outcomes are children's self-reported pain and observer-rated pain behavior. Secondary outcomes include physiological responses (heart rate and oxygen saturation) and behavioral cooperation scores. The study will compare changes in these measures across the four intervention groups.

What is the purpose of this research? The findings from this trial are expected to provide evidence to help dentists choose the most effective comfort measures to keep children calm and pain-free during lower jaw injections. The study aims to clarify whether distraction-based methods (cooling+vibration or counterstimulation) offer advantages over simply changing the needle gauge.

Were there any side effects or risks? Safety is being monitored continuously throughout the procedure via pulse oximetry (oxygen saturation) and heart rate tracking. The interventions are considered low-risk, and children who show excessive distress are withdrawn and managed according to standard care.

Who paid for this study? The study received no outside funding. The authors declared no conflicts of interest.

Where was the study done? Department of Pediatric Dentistry, Al-Mustansiriyah University, Baghdad, Iraq.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Study Design This is a prospective, parallel-group, randomized controlled clinical trial (RCT) conducted at the Department of Pediatric Dentistry, Al-Mustansiriyah University College of Dentistry, Baghdad, Iraq. The trial is designed to compare the effectiveness of three interventions versus a standard control in reducing pain, physiological stress, and behavioral distress during inferior alveolar nerve block (IANB) in pediatric dental patients.

Participants A total of 166 medically healthy children (ASA I or II) aged 5 to 9 years, who required dental treatment under IANB, were enrolled. Inclusion criteria included a baseline Frankl Behavior Rating of 2 or 3 (cooperative or potentially cooperative). Exclusion criteria were systemic illness, neurological or developmental conditions affecting pain perception, previous traumatic dental injection experience, allergy to lidocaine or epinephrine, and significant respiratory or cardiovascular conditions.

Randomization and Allocation Children were randomly assigned to one of four groups using a sealed-envelope method to ensure allocation concealment. Group sizes: Cooling + Vibration (n=40), Counterstimulation (n=41), 30-gauge needle (n=43), and standard 27-gauge needle control (n=42).

Interventions All injections use 2% lidocaine with 1:100,000 epinephrine, administered at a controlled rate of 1 mL/min by calibrated pediatric dentists.

Cooling + Vibration group: A thermomechanical device (Buzzy®, MMJ Labs, USA) is applied externally to the injection site for 30-60 seconds before needle insertion and remains in place during anesthetic deposition. The device provides simultaneous cooling and vibration.

Counterstimulation group: Gentle manual tapping or pressure with a cotton roll is applied adjacent to the injection site throughout the procedure.

30-gauge needle group: IANB is performed using a long 30-gauge needle without any distraction technique.

Standard control group (27-gauge needle): Routine IANB using a long 27-gauge needle, representing standard clinical practice.

Outcome Measures

Primary outcomes:

Child self-reported pain using the Wong-Baker FACES Pain Rating Scale (0-10) immediately post-injection.

Observer-rated pain behavior using the FLACC scale (Face, Legs, Activity, Cry, Consolability; 0-10) during the injection.

Secondary outcomes:

Heart rate (beats per minute) and oxygen saturation (%) continuously recorded via pediatric pulse oximetry.

Behavioral cooperation assessed with the Frankl Behavior Rating Scale (1-4).

All outcome assessments are performed by a blinded, calibrated observer. Children provide self-reported pain scores immediately after the injection using age-appropriate instructions.

Statistical Analysis Descriptive statistics will summarize baseline characteristics. Paired t-tests will compare within-group changes from baseline to follow-up. One-way analysis of variance (ANOVA) with Bonferroni post-hoc corrections will be used for between-group comparisons. The level of statistical significance is set at p < 0.05. Analyses will be performed using IBM SPSS version 28.

Ethical Approval The study protocol was approved by the Institutional Review Board of Al-Mustansiriyah University College of Dentistry (clinical trial number: MUPEDO4, REC199). Written informed consent was obtained from parents or legal guardians, and assent was obtained from children. The study complies with the Declaration of Helsinki (2013). Children who become excessively distressed are withdrawn and managed according to standard care.

Trial Registration (If applicable, the registry number and date would be entered here; the document lists an internal number MUPEDO4, REC199.

Study Type

Interventional

Enrollment (Actual)

166

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Iraq
    • Rusafa
      • Baghdad, Rusafa, Iraq, 10001
        • Al-Mustansiriyah University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Children aged 5 to 9 years. Requiring dental procedures under inferior alveolar nerve block (IANB) anesthesia.

Medically healthy children classified as American Society of Anesthesiologists (ASA) Class I or II.

Baseline Frankl Behavior Rating of 2 or 3 (indicating cooperative or potentially cooperative behavior).

Written informed consent obtained from parents or legal guardians. Age-appropriate assent obtained from the child. -

Exclusion Criteria:

Presence of systemic illness.

Neurological disorders.

Developmental conditions affecting pain perception.

Previous traumatic dental injection experiences.

Allergy or hypersensitivity to lidocaine with epinephrine.

Significant respiratory or cardiovascular conditions (to avoid confounding physiological monitoring).

Children who exhibit excessive distress during the procedure will be withdrawn and treated per standard care (this can be added as a withdrawal criterion if needed).

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cooling + Vibration
A thermomechanical device (Buzzy™, MMJ Labs, USA) is positioned externally at the injection site for 30-60 seconds before needle insertion and remains in place during anesthetic deposition, providing simultaneous vibration and cooling. The inferior alveolar nerve block (IANB) is performed using 2% lidocaine with 1:100,000 epinephrine delivered at a controlled rate of approximately 1 mL/minute.
Device: Buzzy Device
A thermomechanical device providing simultaneous vibration and cooling, placed externally at the injection site for 30-60 seconds before and during local anesthetic deposition.
Drug: Lidocaine hydrochloride 2% with epinephrine 1:100 000
2% lidocaine with 1:100,000 epinephrine administered as a local anesthetic for the inferior alveolar nerve block at 1 mL/min.
Experimental: Counterstimulation
Gentle manual tapping and pressure with a cotton roll adjacent to the injection site is applied throughout the injection to provide non-noxious tactile input and attentional distraction. The IANB is performed using 2% lidocaine with 1:100,000 epinephrine delivered at a controlled rate of approximately 1 mL/minute.
Drug: Lidocaine hydrochloride 2% with epinephrine 1:100 000
2% lidocaine with 1:100,000 epinephrine administered as a local anesthetic for the inferior alveolar nerve block at 1 mL/min.
Procedure: Counterstimulation
Gentle manual tapping and pressure applied with a cotton roll adjacent to the injection site throughout the injection to provide tactile distraction.
Experimental: 30-Gauge Needle
A standard IANB is performed using a 30-gauge long needle without additional distraction techniques. The anesthetic used is 2% lidocaine with 1:100,000 epinephrine delivered at a controlled rate of approximately 1 mL/minute.
Drug: Lidocaine hydrochloride 2% with epinephrine 1:100 000
2% lidocaine with 1:100,000 epinephrine administered as a local anesthetic for the inferior alveolar nerve block at 1 mL/min.
Device: 30-Gauge Needle
A 30-gauge long dental needle used for the inferior alveolar nerve block.
Active Comparator: Standard 27G Needle (Control)
A routine IANB is performed using a standard 27-gauge long needle as the control condition. The anesthetic used is 2% lidocaine with 1:100,000 epinephrine delivered at a controlled rate of approximately 1 mL/minute. This represents the current standard of care.
Drug: Lidocaine hydrochloride 2% with epinephrine 1:100 000
2% lidocaine with 1:100,000 epinephrine administered as a local anesthetic for the inferior alveolar nerve block at 1 mL/min.
Device: 27-Gauge Needle
A 27-gauge long dental needle used for the inferior alveolar nerve block (standard control).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Wong-Baker FACES Pain Rating Scale
Time Frame: Time Frame: Immediately post-procedure
Description: Self-reported pain intensity assessed by the child immediately after the inferior alveolar nerve block (IANB) injection. The scale ranges from 0 to 10, where 0 indicates "no pain" and 10 indicates "worst possible pain." Children select the face that best matches their pain experience.
Time Frame: Immediately post-procedure
FLACC Scale (Face, Legs, Activity, Cry, Consolability)
Time Frame: Periprocedural
Description: Observer-rated behavioral pain assessment scored by a blinded, calibrated observer during the injection procedure. The scale evaluates five behavioral categories (Face, Legs, Activity, Cry, Consolability), each scored 0-2, for a total score ranging from 0 to 10. Higher scores indicate greater pain and distress.
Periprocedural

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart Rate (bpm)
Time Frame: Periprocedural
Description: Assessed continuously during injection via pulse oximetry.
Periprocedural
Oxygen Saturation
Time Frame: Periprocedural
Assessed continuously during injection via pulse oximetry
Periprocedural
Frankl Behavior Rating Scale
Time Frame: Periprocedural
Observer-rated behavioral cooperation assessed during the procedure.
Periprocedural

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Al-Mustansiriyah University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2025

Primary Completion (Actual)

September 30, 2025

Study Completion (Actual)

September 30, 2025

Study Registration Dates

First Submitted

June 16, 2026

First Submitted That Met QC Criteria

June 19, 2026

First Posted (Actual)

June 25, 2026

Study Record Updates

Last Update Posted (Actual)

June 25, 2026

Last Update Submitted That Met QC Criteria

June 19, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MUPEDO4

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be shared because this study involves a vulnerable pediatric population (children aged 5-9 years). Informed consent obtained from parents/guardians did not include provisions for sharing de-identified data with external researchers. Additionally, institutional policies at Al-Mustansiriyah University restrict the sharing of pediatric health data to protect patient privacy and confidentiality. No data-sharing agreement or repository has been established for this single-center trial.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain Management

Clinical Trials on Buzzy Device

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe